Frederic Maloisel
Overview
Explore the profile of Frederic Maloisel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1718
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le Du K, Septans A, Maloisel F, Vanquaethem H, Schmitt A, Le Goff M, et al.
J Med Internet Res
. 2023 Feb;
25:e38619.
PMID: 36790852
Background: Evidence regarding the analgesic effect of distraction through immersion in virtual reality (VR) for care-induced pain has been documented in several phase 2 trials, but comparison with standard treatments...
2.
Claustre G, Boulanger C, Maloisel F, Etienne-Selloum N, Fornecker L, Durot E, et al.
J Cancer Res Clin Oncol
. 2022 Jul;
149(5):1883-1893.
PMID: 35789429
Purpose: Rituximab (R) or obinutuzumab (G) combined with CHOP chemotherapy are used in previously untreated follicular lymphoma (FL). The aim is to compare in real life setting the efficacy and...
3.
Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler A, Maloisel F, Rea D, et al.
Leukemia
. 2021 Jan;
35(8):2332-2345.
PMID: 33483613
The STI571 prospective randomised trial (SPIRIT) French trial is a four-arm study comparing imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg + cytarabine (AraC), and IM 400 ...
4.
Andres E, Lorenzo Villalba N, Mourot-Cottet R, Maloisel F, Tebacher M, Gottenberg J, et al.
Medicines (Basel)
. 2020 Mar;
7(3).
PMID: 32204561
The most important series devoted to antithyroid drug-induced severe neutropenia and agranulocytosis are Japanese studies, almost specifically in relation to the intake of methimazole. The clinical data of 30 Caucasian...
5.
Lescuyer S, Ledoux M, Gravier S, Natarajan-Ame S, Duval C, Maloisel F, et al.
Int J Infect Dis
. 2019 Jan;
80:134-136.
PMID: 30639623
Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis. Only one patient (0.2%) was diagnosed with tuberculosis among the 485 patients receiving...
6.
Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, et al.
Haematologica
. 2018 Oct;
104(3):497-504.
PMID: 30287621
Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in patients with lower-risk myelodysplastic syndrome. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective...
7.
Kreitman R, Dearden C, Zinzani P, Delgado J, Karlin L, Robak T, et al.
Leukemia
. 2018 Jul;
32(8):1768-1777.
PMID: 30030507
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study...
8.
Andres E, Mourot-Cottet R, Maloisel F, Keller O, Vogel T, Severac F, et al.
J Clin Med
. 2017 Sep;
6(10).
PMID: 28954408
Background: Despite major advances in its prevention and treatment, febrile neutropenia remains a most concerning complication of cancer chemotherapy. Outside the oncology setting, however, only few data are currently available...
9.
Andres E, Mourot-Cottet R, Maloisel F, Vogel T, Tebacher M, Gottenberg J
Eur J Intern Med
. 2017 Aug;
46:e13-e14.
PMID: 28823525
No abstract available.
10.
Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, et al.
Haematologica
. 2017 May;
102(8):1368-1377.
PMID: 28522576
Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatinib. However, questions remain unanswered...